our mission
Improving quality of life for millions of people with chronic pain
At Remedee Labs, we understand that chronic pain is far more than just a physical sensation. Its impact is wide-reaching, significantly affecting quality of life. It disrupts sleep, increases stress, and limits mobility—creating a vicious cycle that deeply affects daily life, social interactions, and professional activity.
That’s why, since 2016, we’ve been committed to developing innovative, drug-free solutions—clinically validated—to transform the lives of millions of people living with chronic pain, through our unique millimeter wave neuromodulation technology.
About Remedee Labs
Founded in 2016, Remedee Labs is a French company specializing in the non-pharmaceutical treatment of chronic pain. Remedee Labs is the inventor of the first millimeter wave wristband, protected by over 12 international patents.
After several years of research and clinical studies conducted in collaboration with Pain Management Centers (CETD), Remedee Labs has demonstrated the effectiveness of this non-pharmaceutical, non-invasive approach in treating rheumatic pain.
Millimetre wave-based neuromodulation : Millimetre wave-based neuromodulation
Developed in France after more than 10 years of research, Remedee Labs’ technology is now:
Certified as a medical device (Class IIa) for the management of fibromyalgia symptoms and osteoarthritis-related pain
Clinically validated through two studies conducted in partnership with leading research centers and hospitals
Integrated into a personalized care program for comprehensive support and follow-up
Our Story
Launch of the NoviRem™ and FibroRem™ Medical Solutions
Remedee Labs is now offering two new clinically validated medical solutions: NoviRem and FibroRem, specifically designed to support patients living with osteoarthritis or fibromyalgia.
CE Medical Certification for Osteoarthritis in Europe
CE medical certification for osteoarthritis opens up new therapeutic possibilities, offering a non-pharmaceutical and complementary option to conventional treatments for alleviating osteoarthritis pain.
2025
CE Medical Certification for Fibromyalgia in Europe
First Medical Device Authorized in Europe for Fibromyalgia Treatment
Remedee Labs’ solution becomes the first clinically validated and CE-certified medical device in Europe for alleviating fibromyalgia symptoms, a condition for which no specific treatment had previously been indicated.
encore été indiqué jusqu’à présent.
2024
Positive Clinical Results in Osteoarthritis and Fibromyalgia
Remedee Labs has announced positive results from its clinical trials in osteoarthritis and fibromyalgia, showing a significant reduction in pain, improvement in sleep quality, and an overall better quality of life for patients.
UPSA and Remedee Labs Announce Partnership
Medical representatives responsible for promoting UPSA medications will meet with healthcare professionals to introduce them to Remedee Labs’ technology.
2023
The FDA grants "Breakthrough Designation Device" status.
The U.S. Food & Drug Administration (FDA) has granted “Breakthrough Device” status to Remedee Labs for its solution in managing patients suffering from fibromyalgia.
Series A Funding Round
Announcement of a €12.2 Million Series A Funding Round
2022
Remedee Labs joins Future4Care
Integration of the Digital Health Startup Accelerator Future4Care
Launch of the Two Clinical Trials
Remedee Labs has announced the launch of two clinical trials, one for osteoarthritis and the other for fibromyalgia.
2021
Launch of a Clinical Trial on Migraine
Launch of a Clinical Trial to Prove the Effect of Millimeter Waves on Migraines
2020
Seed Funding Round
Announcement of an €11 Million Seed Funding Round
ISO 13485 Certification
Remedee Labs has achieved ISO 13485 certification, ensuring that its quality management system meets the rigorous standards required for the design and manufacture of medical devices.
2019
First Tests!
- First Tests of the MEET Module in a Miniaturized Device
- Clinical Validation of the Safety of Millimeter Wave Treatment
2018
Patent Filings
Remedee Labs has filed patents for the development of the MEET technology, an integrated module of a millimeter wave emission system designed for medical use.
2017
Creation of Remedee Labs
Creation of Remedee Labs and Winner of the BPI National iLab Research and Innovation Competition
2016
A teams of experts
Remedee Labs is today a multidisciplinary, international team of 30 people. Our areas of expertise cover medical research, microelectronics, software development, artificial intelligence and more.
At the heart of our ambitious project are people and human values.
David CROUZIER
Co-founder and co-CEO David Crouzier has 15 years’ experience in the field of biomedical research. A recognized authority, Crouzier was previously head of a French Department of Defense research laboratory. His research into non-ionizing radiation and electromagnetic biological effects has contributed to publications on health and safety risks of emerging technologies for the National Agency for Food Safety, the Environment and Work (ANSES) in France.
Gilles LITMAN
Graduate of ESSEC Paris, Gilles has over 20 years’ experience in the pharmaceutical industry, especially strategy, international development and business management. Before joining Remedee Labs, Gilles was the VP of Digital Health at Sanofi, where he worked on digital platforms focused on diabetes and cardiovascular diseases.
Michael FOERSTER
Co-founder and CTO Michael Foerster is an expert in implanted medical devices and health technology innovation, Foerster has also worked on the design of active implantable brain-machine interfaces for quadriplegic patients at the CEA-Clinatec medical technology research center in Grenoble. He is also a multiple high-tech entrepreneur, having also co-founded mountain sport technology company NIVOLOG.
Jacques HUSSER
Co-founder and Exec Chairman Jacques Husser served most recently as COO of French IoT company Sigfox, recognized as one of France’s highly successful startups and now a global leader in IoT wireless networks and services. Having raised over €300m and establishing itself in over 60 countries, Sigfox is now a key international technology company. An expert in business strategy, vision and organization, Husser has also held leadership positions in a telehealth company, as well as heading one of the Building Automation divisions of the Hager group.
Scientific advisory board
Comprised of leading experts in neuromodulation, pain management and electromagnetic waves the Scientific Advisory Board provides strategic and scientific counsel to advance the development of Remedee Labs’ solution.
Thierry BOSC
President of Remedee Labs’ scientific advisory board & Director of the CEA-Clinatec endowment fund
Dr. Caroline MAINDET
Grenoble teaching hospital / Doctor at the Center for Pain Management
Pr. Pierre ALBALADEJO
Grenoble teaching hospital, Department of Anesthesia & Intensive care
Dr. Yves LE DREAN
Rennes 1 University – IRSET – Inserm UMR 1085, Expert in the biological effects of electromagnetic waves
Pr. Alain SERRIE (MD-PhD)
Head of the department of Pain Medicine & Palliative Care, President & founder of the Douleur sans frontières association
